Data Shows Robust Options for Acute Management
Peer-reviewed research in Antiviral Research reveals the clinical impact of treatments and immune-supportive protocols. WASHINGTON, Feb. 11, 2026 /PRNewswire/ —…
Read More
The Times Of Bengal
For You Forever Yours
Alley Cat Allies Provides 600+ Cats with No-Cost Spay and Neuter and Food in Des Moines, Iowa
DES MOINES, Iowa, Feb. 11, 2026 /PRNewswire/ — Nearly 200 cat caregivers in the Des Moines, Iowa, area received no-cost…
Read More
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034)
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma),…
Read More
In HelloNation, Periodontics Expert Dr. Danika Crabtree of Warwick, RI, Explains Why Gum Disease Deserves More Attention Than You Think
WARWICK, R.I., Feb. 11, 2026 /PRNewswire/ — Why do so many people ignore the early signs of gum disease until…
Read More
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and…
Read More
CNO Financial Group Declares $0.17 Quarterly Dividend and Announces Virtual Annual Meeting Date
Director Nina Henderson to retire CARMEL, Ind., Feb. 11, 2026 /PRNewswire/ — CNO Financial Group, Inc. (NYSE: CNO) announced today…
Read More
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase…
Read More
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year…
Read More
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25…
Read More
Barzolvolimab Provides Long-Term Improvements for Spontaneous Urticaria
After 52 weeks of barzolvolimab, participants saw continued treatment efficacy an additional 28 weeks after their last dose MILWAUKEE, Feb.…
Read More
